TrialArthritis and rheumatism2012

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

William Stohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.